Relación de la expresión génica de IP-10 con la actividad del lupus eritematoso sistémico / Relationship of IP-10 gene expression to systemic lupus erythematosus activity

Objetivo: Evaluar la expresión génica del gen IP-10 en pacientes con lupus eritematoso sistémico (LES) y su posible relación con la actividad de la enfermedad. Pacientes y métodos: El estudio incluyó 120 pacientes diagnosticados con LES y 30 controles sanos. Se investigó la expresión génica relativa de IP-10 con el método fold change, la cual fue correlacionada con el nivel de actividad lúpica evaluado con el instrumento SLEDAI 2-K. Resultados: Se encontraron diferentes niveles en la expresión génica de IP-10 relacionada con la actividad lúpica (p =<0,001). Estos fueron mayores en los pacientes con actividad grave respecto a aquellos sin actividad, baja y moderada. El incremento en la expresión génica del grupo con actividad grave fue significativo con un fold change de tres. Conclusión: El incremento significativo en la expresión génica relativa IP-10 puede ser un marcador de actividad lúpica grave.(AU)

Objectives: To evaluate IP-10 gene expression in patients with SLE, and its possible relationship with disease activity. Patients and methods: This study included 120 patients diagnosed with SLE and 30 healthy controls. The relative gene expression of IP-10 was investigated with the Fold Change method, which was correlated with the level of lupus activity evaluated with the SLEDAI 2-K instrument. Results: Different levels of gene expression were found according to the SLE activity (p =<0.001). IP-10 gene expression levels were higher in patients with severe activity than in those with no activity, low activity, and moderate activity. The increase in gene expression in the severe activity group was significant with a Fold Change of 3. Conclusion: The significant increase in relative gene expression IP-10 may be a marker of severe lupus activity.(AU)

Relationship of IP-10 gene expression to systemic lupus erythematosus activity.

OBJECTIVES: To evaluate IP-10 gene expression in patients with SLE, and its possible relationship with disease activity. PATIENTS AND METHODS: This study included 120 patients diagnosed with SLE and 30 healthy controls. The relative gene expression of IP-10 was investigated with the Fold Change method, which was correlated with the level of lupus activity evaluated with the SLEDAI 2-K instrument. RESULTS: Different levels of gene expression were found according to the SLE activity (P = <.001). IP-10 gene expression levels were higher in patients with severe activity than in those with no activity, low activity, and moderate activity. The increase in gene expression in the severe activity group was significant with a Fold Change of 3 CONCLUSION: The significant increase in relative gene expression IP-10 may be a marker of severe lupus activity.

Relationship of IP-10 gene expression to systemic lupus erythematosus activity. / Relación de la expresión génica de IP-10 con la actividad del lupus eritematoso sistémico.

OBJECTIVES: To evaluate IP-10 gene expression in patients with SLE, and its possible relationship with disease activity. PATIENTS AND METHODS: This study included 120 patients diagnosed with SLE and 30 healthy controls. The relative gene expression of IP-10 was investigated with the Fold Change method, which was correlated with the level of lupus activity evaluated with the SLEDAI 2-K instrument. RESULTS: Different levels of gene expression were found according to the SLE activity (p =<0.001). IP-10 gene expression levels were higher in patients with severe activity than in those with no activity, low activity, and moderate activity. The increase in gene expression in the severe activity group was significant with a Fold Change of 3. CONCLUSION: The significant increase in relative gene expression IP-10 may be a marker of severe lupus activity.

Tocilizumab in glucocorticoid-resistant graves orbitopathy. A case series report of a mexican population.

PURPOSE: To describe pre- to post-treatment changes in clinical activity score (CAS) and exophthalmometry in patients with Graves orbitopathy treated with tocilizumab (TCZ). MATERIAL AND METHODS: Eight Mexican patients presenting with active Graves orbitopathy (CAS>3/7) previously treated with glucocorticoids received 1 monthly dose of TCZ for 6 months. CAS, EUGOGO severity assessment and exophthalmometry were used to evaluate clinical status, with serum measurement of thyroid-stimulating hormone receptor antibodies (TR-Ab) for biochemical evaluation before and after application of TCZ. RESULTS: Eight patients were analyzed: 6 male (75%), 2 female (25%): mean age, 45.9±11.2 years; mean weight, 85±18.3 kg. Mean TR-Ab level at treatment outset was 291.9±96.4%, mean CAS 4.1±0.3 and mean exophthalmometry 21.2±3.2 mm. After TCZ treatment, mean TR-Ab level fell to 172.7±54% (P=0.001), mean CAS to 1.1±0.6 (P=0.001) and mean exophthalmometry to 19.3±2 mm (P=0.02). CONCLUSIONS: TCZ is a therapeutic option for glucocorticoid-resistant orbitopathy, and should be considered in second line due to the cost of treatment or in first line in patients with contraindications to intravenous GC pulse therapy.